Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response study of erythropoietin on frataxin in Friedreich's ataxia
2007-004919-55Phase 2Completed
- Sponsor
- Medical University of Innsbruck, University Clinic for Neurology
- Start
- Oct 2007
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of epoetin beta in Friedreich ataxia (FA) (3 arms), sponsored by Medical University of Innsbruck, University Clinic for Neurology. Primary endpoint: Dose-response relationship between erythropoietin dose and frataxin upregulation. Started Oct 2007; status: completed.
02
Drugs
epoetin beta
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on 2007-004919-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004919-55.